1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Strategy

Marinomed Exploring Options For Virus-Blocking OTC Nasal Spray Platform

 
• By Tom Gallen

The virus-blocking platform used in OTC nasal sprays marketed by Perrigo and Reckitt, amongst others, developed by Austria's Marinomed is up for sale.

nasal spray
• Source: Shutterstock

Austrian biotech Marinomed is weighing up strategic options for its virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo, Reckitt and Procter & Gamble for use in OTC nasal sprays.

Having appointed an external advisor, Marinomed said it has initiated a process to begin engaging with interested parties to discuss potential

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By Tom Gallen

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

PharmaSGP Targets More Of The Same As It Outperforms OTC Market

 
• By Tom Gallen

Germany-based firm grew three-times faster than the OTC pharmacy market in 2024 and is hoping to continue this momentum in 2025.

Reckitt Leans On Intimate Wellness Brands As OTC Stumbles

 
• By Tom Gallen

Gains for its Intimate Wellness portfolio - including a strong showing from Durex - helped offset lower sales of Reckitt's OTC cold & flu remedies in Q1. CEO Kris Licht shared his thoughts on the impact of US tariffs on the business and planned future divestments.

More from Business